1. Home
  2. PHAT vs NIE Comparison

PHAT vs NIE Comparison

Compare PHAT & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$9.62

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$26.88

Market Cap

745.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAT
NIE
Founded
2018
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
894.0M
745.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
PHAT
NIE
Price
$9.62
$26.88
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$19.83
N/A
AVG Volume (30 Days)
1.2M
64.8K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
N/A
9.04%
EPS Growth
42.72
N/A
EPS
N/A
N/A
Revenue
$175,110,000.00
N/A
Revenue This Year
$93.04
N/A
Revenue Next Year
$58.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
216.93
N/A
52 Week Low
$4.25
$22.74
52 Week High
$18.31
$27.02

Technical Indicators

Market Signals
Indicator
PHAT
NIE
Relative Strength Index (RSI) 31.78 65.39
Support Level N/A $24.71
Resistance Level $12.83 $27.02
Average True Range (ATR) 0.72 0.32
MACD -0.26 -0.03
Stochastic Oscillator 2.57 91.92

Price Performance

Historical Comparison
PHAT
NIE

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

Share on Social Networks: